Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
AVENTURA, Fla., July 14, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse Science, Inc. ( www.fusescience.com ), announced today that it has entered into a research and development agreement with Platform Delivery Technologies Inc. (PDT Inc.), a California-based pharmaceutical consulting firm. Double Eagle Holdings is the parent company of Fuse Science, Inc., the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.
The team at PDT Inc. has been responsible for numerous product formulations currently on the market, including line extensions for Chloraseptic, private label electrolyte replacement formulas for national drugstore chains, Zicam Cold formulas and several prescription pharmaceuticals. The PDT Inc. team has more than 30 pending and issued patents in the pharmaceutical and sports performance industries.
"PDT Inc. has provided exclusive formulations and proprietary branding for many of the world's top pharmaceutical companies. Through this agreement, our ability to bridge into several major product categories is a certainty," said Brian Tuffin, Fuse Science President and Chief Operating Officer. "Our strong working relationship will accelerate our commercialization efforts."
Under the terms of the agreement, PDT Inc. will oversee a team of scientists facilitating the formulation and manufacturing of several Fuse Science products that leverage the Company's industry-leading Fusome Technology. The team's focus will be ongoing product innovation while working to advance Fuse Science's technology, intellectual property and patents. Rob Davidson, the team's managing director, reported today that PDT Inc. has already completed work on three new industry standards and proprietary formulations as Fuse Science prepares to enter the sports nu